Novartis announced the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint. Read more...
BASE10 Genetics, DNA Link announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting. More news...
Anixa Biosciences and OntoChem GmbH have verified one of their recently discovered compounds is similar in potency to remdesivir, the only approved anti-viral drug against SARS-Cov-2. Read more...
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.